<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Ulster Med J</journal-id><journal-id journal-id-type="iso-abbrev">Ulster Med J</journal-id><journal-id journal-id-type="pmc-domain-id">461</journal-id><journal-id journal-id-type="pmc-domain">ulstermedj</journal-id><journal-id journal-id-type="publisher-id">umj</journal-id><journal-title-group><journal-title>The Ulster Medical Journal</journal-title></journal-title-group><issn pub-type="ppub">0041-6193</issn><issn pub-type="epub">2046-4207</issn><publisher><publisher-name>Ulster Medical Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12476126</article-id><article-id pub-id-type="pmcid-ver">PMC12476126.1</article-id><article-id pub-id-type="pmcaid">12476126</article-id><article-id pub-id-type="pmcaiid">12476126</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Clinical Paper</subject></subj-group></article-categories><title-group><article-title>Mutation characterisation of the cystic fibrosis transmembrane conductance regulator (CFTR) gene in people with cystic fibrosis in Northern Ireland</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Blevings</surname><given-names initials="PJ">Philippa J.</given-names></name><xref rid="af1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Moore</surname><given-names initials="JE">John E.</given-names></name><xref rid="af1" ref-type="aff">1</xref><xref rid="af2" ref-type="aff">2</xref><xref rid="af3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>McCaughan</surname><given-names initials="J">John</given-names></name><xref rid="af4" ref-type="aff">4</xref><xref rid="af5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Reid</surname><given-names initials="A">Alastair</given-names></name><xref rid="af5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rendall</surname><given-names initials="JC">Jacqueline C</given-names></name><xref rid="af3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Millar</surname><given-names initials="BC">Beverley C.</given-names></name><xref rid="af1" ref-type="aff">1</xref><xref rid="af2" ref-type="aff">2</xref><xref rid="af3" ref-type="aff">3</xref><xref rid="C1" ref-type="corresp">*</xref></contrib><aff id="af1"><label>1</label>School of Medicine, Dentistry and Biomedical Sciences, The Wellcome-Wolfson Institute for Experimental Medicine, Queen&#8217;s University, 97 Lisburn Road, Belfast BT9 7BL, Northern Ireland, UK</aff><aff id="af2"><label>2</label>Laboratory for Disinfection and Pathogen Elimination Studies, Northern Ireland Public Health Laboratory, Belfast City Hospital, Lisburn Road, Belfast, BT9 7AD, Northern Ireland, UK</aff><aff id="af3"><label>3</label>Northern Ireland Regional Adult Cystic Fibrosis Centre, Level 8, Belfast City Hospital, Lisburn Road, Belfast, Northern Ireland, BT9 7AB, UK</aff><aff id="af4"><label>4</label>Department of Medical Microbiology, The Royal Group of Hospitals, Grosvenor Road, Belfast, BT12 6BA, Northern Ireland, UK</aff><aff id="af5"><label>5</label>Royal Belfast Hospital for Sick Children, Grosvenor Road, Belfast, BT12 6BA, Northern Ireland, UK.</aff></contrib-group><author-notes><corresp id="C1"><label>*</label><bold>corresponding author:</bold> Professor Beverley Cherie Millar, <bold>Email:</bold><email>bcmillar@niphl.dnet.co.uk</email> Northern Ireland Public Health Laboratory, Belfast City Hospital, Lisburn Road, Belfast, BT9 7AD, Northern Ireland, UK.</corresp></author-notes><pub-date pub-type="epub"><day>30</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="ppub"><month>9</month><year>2025</year></pub-date><volume>94</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">497714</issue-id><fpage>64</fpage><lpage>76</lpage><pub-history><event event-type="pmc-release"><date><day>01</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>28</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-28 21:25:17.150"><day>28</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 Ulster Medical Society</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncsalicense">https://creativecommons.org/licenses/by-nc-sa/4.0/</ali:license_ref><license-p>The Ulster Medical Society grants to all users on the basis of a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International Licence the right to alter or build upon the work non-commercially, as long as the author is credited and the new creation is licensed under identical terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="umj-94-2-64.pdf"/><abstract><sec><title>Background</title><p>Cystic fibrosis (CF), which is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene is the most common life-limiting autosomal recessive genetic disease in Northern Ireland. Currently, Northern Ireland has approximately 520 people with CF (PwCF) (312 adults, 208 children) and a defective gene carrier rate of 1 in 22 persons, with approximately 86,507 carriers within the general population. Advances in DNA sequencing technology has allowed for better genetic characterisation of CFTR mutations. The aim of this project was to (i) examine current CFTR mutation frequency and type in paediatric and adult CF populations in Northern Ireland, (ii) examine CFTR mutational trends in relation to CF patients&#8217; age groups, (iii) compare Northern Ireland CFTR most common allele frequencies with those documented globally and (iv) establish a reference/baseline of CFTR mutation information prior to the effect of CFTR modulator therapy.</p></sec><sec><title>Methods</title><p>Anonymised data comprising of birth year, sex, and known alleles of adult and paediatric individuals (n=520) from the Northern Ireland CF population was examined. Alleles were recorded according to legacy, protein and cDNA name and organised by mutation class and type, in accordance with CFTR2 database nomenclature. Individual known alleles frequencies from the complete Northern Ireland CF population (n=1005) were calculated and compared with the CFTR2 database, globally with CFTR data obtained from CF national registries.</p></sec><sec><title>Results</title><p>Within the Northern Ireland CF population, there were 61 different CFTR mutational variants identified in a population of 1005 alleles. In descending occurrence, the most common was F508del with 626 alleles (62.3%), followed by R117H (8.9%), G551D (5.0%), G542X (3.3%), R560T (2.8%) and P67L (2.2%). The remaining alleles were present at a frequency of &lt;2.0%. The six most frequently detected CFTR mutations accounted for 84.4% of all alleles. Over approximately two and a half decades (1996-2021), 23 CFTR mutations remain shared. Six alleles, which were described in the 1996 CFTR analysis, were absent from the 2021 data, whilst there were additional descriptions of 39 allelic mutations, which occurred in the 2021 analysis, but which were not described in the 1996 analysis.</p></sec><sec><title>Conclusion</title><p>Characterisation of CFTR mutation alleles from people with cystic fibrosis provides essential information to help predict disease severity and effect of targeted CFTR modulator therapy. These 2021 data provide a valuable genetic update from the 1996 data and a reference point on the status of the Northern Ireland CFTR mutation types and frequencies. CFTR modulator therapy has the potential to indirectly alter the current <italic toggle="yes">status quo</italic> and distribution of CFTR mutation types amongst children of PwCF, due to improved clinical status and fecundity. Revisiting this in a decade from now will allow an estimation of the indirect influence of CFTR modulator therapy on CFTR mutation evolution.</p></sec></abstract><kwd-group><kwd>allele</kwd><kwd>cystic fibrosis</kwd><kwd>CF</kwd><kwd>CFTR</kwd><kwd>F508del</kwd><kwd>mutations</kwd><kwd>Northern Ireland</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Cystic fibrosis (CF) is the most common life-shortening autosomal recessive disease in Caucasians, with a prevalence of 1 in 2,500 live births in Europe.<xref rid="b1" ref-type="bibr">1</xref> Both life span and quality are affected with devastating multi-system involvement, particularly with the respiratory and gastrointestinal systems.<xref rid="b2" ref-type="bibr">2</xref>,<xref rid="b3" ref-type="bibr">3</xref> CF is caused by cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations, and greater than 2,000 variants are now recognised, grouped into six classes (<xref rid="f01" ref-type="fig">Figure 1</xref>).<xref rid="b4" ref-type="bibr">4</xref> Despite wide allelic diversity, one mutation F508del, involving a phenylalanine deletion at CFTR residue 508, accounts for approximately 70% of alleles worldwide.<xref rid="b5" ref-type="bibr">5</xref></p><fig position="float" id="f01" orientation="portrait"><label>Figure 1:</label><caption><title>Molecular defects of the cystic fibrosis transmembrane conductance regulator (CFTR) mutations and therapeutic approaches developed</title><p>CFTR, cystic fibrosis transmembrane conductance regulator</p><p>Drugs already in use by CF patients are noted in bold.</p><p>* Read through compounds promote the read through of premature termination codons in CFTR mRNA.</p><p>** correctors improve the processing with delivery of functional CFTR protein to the cell surface</p><p>*** potentiators increase the function of CFTR channels on the cell surface.</p><p>(Reproduced from Deletang K, Taulan-Cadars M. Splicing mutations in the CFTR gene as therapeutic targets.</p><p><italic toggle="yes">Gene Ther</italic>. 2022;<bold>29</bold>:399&#8211;406. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.1038/s41434-022-00347-0" ext-link-type="uri">https://doi.org/10.1038/s41434-022-00347-0</ext-link> under a Creative Commons Attribution 4.0 International (CC BY-NC 4.0) Licence (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/" ext-link-type="uri">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="umj-94-2-64-g001.jpg"/></fig><p>The CFTR gene encodes a chloride channel, regulating fluid, pH and electrolytes in mucosal membranes and is important in lung antimicrobial defence.<xref rid="b6" ref-type="bibr">6</xref> Altered CFTR function has wide-ranging detrimental effects, resulting in a progressive pathophysiological cascade, including pancreatic insufficiency, meconium ileus, defective mucociliary clearance, inflammation, pathogen colonisation and ultimately, respiratory failure.<xref rid="b6" ref-type="bibr">6</xref>-<xref rid="b8" ref-type="bibr">8</xref> The leading cause of morbidity and mortality is lung disease, initiated by inflammation, infection, and accumulated mucus obstructing pulmonary parenchyma.<xref rid="b7" ref-type="bibr">7</xref> CF lungs are conducive to microbial colonisation, especially with environmental bacteria and fungi, including <italic toggle="yes">Pseudomonas aeruginosa</italic> and <italic toggle="yes">Aspergillus fumigatus</italic>.<xref rid="b9" ref-type="bibr">9</xref> Additional bacterial pathogens can include <italic toggle="yes">Staphylococcus aureus</italic> (SA), <italic toggle="yes">Haemophilus influenzae</italic> and the non-tuberculous mycobacteria (NTMs).<xref rid="b10" ref-type="bibr">10</xref> Microorganisms exploit CF lung environment niches following initial colonisation of the lower respiratory tract, leading to infection with these organisms, which can become chronic.<xref rid="b9" ref-type="bibr">9</xref>,<xref rid="b10" ref-type="bibr">10</xref></p><p>The last formal publication of CFTR mutations types in the Northern Ireland CF population was approximately 27 years ago in 1996.<xref rid="b11" ref-type="bibr">11</xref> Advances in DNA sequencing technology combined with a requirement to know each CF patient&#8217;s CFTR allelic mutations, in order to access the recently licenced CFTR modulator therapies, including ivacaftor and elexacaftor-tezacaftor-ivacaftor (ETI), has produced high quality mutational information, which is now beginning to be published for each country, in order to build up a global picture of CFTR mutation classes and their geographical distribution. The aim of this project was to (i) examine current CFTR mutation frequency and type in paediatric and adult CF populations in Northern Ireland, (ii) examine CFTR mutational trends in relation to CF patients&#8217; age groups, (iii) compare Northern Ireland CFTR allele frequencies with those documented globally and (iv) establish a reference/baseline of CFTR information prior to the effect of CFTR modulator therapy.</p></sec><sec sec-type="methods"><title>Methods</title><p>Anonymised data comprising of birth year, sex, and known alleles of 312 adult and 208 paediatric individuals (n=520) from the Northern Ireland CF population as of December 2021, were examined. Alleles were recorded according to legacy, protein and cDNA name and organised by mutation class and type, in accordance with CFTR2 database nomenclature (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cftr2.org" ext-link-type="uri">www.cftr2.org</ext-link>). Individual known alleles frequencies from the complete Northern Ireland CF population (n=1005) were calculated and compared with the CFTR2 database, globally with CFTR data obtained from CF national registries (<xref rid="t01" ref-type="table">Table 1</xref>).</p><table-wrap position="float" id="t01" orientation="portrait"><label>Table 1.</label><caption><title>Sources of CFTR mutation frequency data</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" rowspan="1" colspan="1">Databases &amp; Registries</th><th align="center" rowspan="1" colspan="1">Available at:</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">CFTR2</td><td align="left" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://cftr2.org" ext-link-type="uri">http://cftr2.org</ext-link>
</td></tr><tr><td align="center" rowspan="1" colspan="1">ECFSPR (2018)</td><td align="left" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ecfs.eu/sites/default/files/general-content-files/working-groups/ecfs-patient-registry/ECFSPR_Report_2018_v1.4.pdf" ext-link-type="uri">https://www.ecfs.eu/sites/default/files/general-content-files/working-groups/ecfs-patient-registry/ECFSPR_Report_2018_v1.4.pdf</ext-link>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Dutch CF Registry (2020)</td><td align="left" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://ncfs.nl/onderzoek-naar-taaislijmziekte/dutch-cf-registry/" ext-link-type="uri">https://ncfs.nl/onderzoek-naar-taaislijmziekte/dutch-cf-registry/</ext-link>
</td></tr><tr><td align="center" rowspan="1" colspan="1">French CF Registry (2017)</td><td align="left" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.vaincrelamuco.org/sites/default/files/french_cf_registry_2017_annual_data_report.pdf" ext-link-type="uri">https://www.vaincrelamuco.org/sites/default/files/french_cf_registry_2017_annual_data_report.pdf</ext-link>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Belgian CF Registry</td><td align="left" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.sciensano.be/en/projects/belgian-cystic-fibrosis-registry" ext-link-type="uri">https://www.sciensano.be/en/projects/belgian-cystic-fibrosis-registry</ext-link>
</td></tr><tr><td align="center" rowspan="1" colspan="1">CFF Registry (2021)</td><td align="left" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cff.org/sites/default/files/2021-11/Patient-Registry-Annual-Data-Report.pdf" ext-link-type="uri">https://www.cff.org/sites/default/files/2021-11/Patient-Registry-Annual-Data-Report.pdf</ext-link>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Canadian CF Registry (2018)</td><td align="left" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://cysticfibrosis.ca/canadian-cystic-fibrosis-registry" ext-link-type="uri">https://cysticfibrosis.ca/canadian-cystic-fibrosis-registry</ext-link>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Irish CF Registry</td><td align="left" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://cfri.ie/annual-reports/" ext-link-type="uri">https://cfri.ie/annual-reports/</ext-link>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Brazilian CF Registry (2017)</td><td align="left" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.gbefc.org.br/ckfinder/userfiles/files/REBRAFC_2017_EN.pdf" ext-link-type="uri">http://www.gbefc.org.br/ckfinder/userfiles/files/REBRAFC_2017_EN.pdf</ext-link>
</td></tr><tr><td align="center" rowspan="1" colspan="1">South African CF Registry (2019-20)</td><td align="left" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://sacfa.org.za/wp-content/uploads/SACFA-CF-RegistryAnnualReport2019-2020.pdf" ext-link-type="uri">https://sacfa.org.za/wp-content/uploads/SACFA-CF-RegistryAnnualReport2019-2020.pdf</ext-link>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Australian CF Registry (2020)</td><td align="left" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cfsa.org.au/acfdr-2020-annual-report/" ext-link-type="uri">https://www.cfsa.org.au/acfdr-2020-annual-report/</ext-link>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Asian CF data</td><td align="left" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubmed.ncbi.nlm.nih.gov/26437683/" ext-link-type="uri">https://pubmed.ncbi.nlm.nih.gov/26437683/</ext-link>
</td></tr><tr><td align="center" rowspan="1" colspan="1">UK CF Registry (2020)</td><td align="left" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cysticfibrosis.org.uk/about-us/uk-cf-registry/reporting-and-resources" ext-link-type="uri">https://www.cysticfibrosis.org.uk/about-us/uk-cf-registry/reporting-and-resources</ext-link>
</td></tr></tbody></table></table-wrap></sec><sec sec-type="results"><title>Results</title><p>Names, characteristics, and frequencies of the mutations identified in the Northern Ireland CF population showing the adult and paediatric data combined are shown in <xref rid="t02" ref-type="table">Table 2</xref>. In the adult Northern Ireland CF population, there was 312 PwCF and 591 alleles. The Northern Ireland CF paediatric population had 208 PwCF and 414 alleles. Altogether, there was 520 PwCF and 1005 known alleles. Sixty one different variants were identified in the Northern Ireland CF population from 1005 alleles. In descending occurrence, the most common was F508del with 626 alleles (62.3%), followed by R117H (8.9%), G551D (5.0%), G542X (3.3%), R560T (2.8%) and P67L (2.2%). The remaining alleles were present at a frequency of &lt;2.0%.</p><table-wrap position="float" id="t02" orientation="portrait"><label>Table 2.</label><caption><title>Names, characteristics, and frequencies of CFTR mutations identified in the Northern Ireland CF population.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" rowspan="2" colspan="1">Variant Legacy Name</th><th align="center" rowspan="2" colspan="1">Variant cDNA Name</th><th align="center" rowspan="2" colspan="1">Variant Protein Name</th><th align="center" rowspan="2" colspan="1">Mutation Type</th><th align="center" rowspan="2" colspan="1">Mutation Category</th><th align="center" rowspan="2" colspan="1">Mutation Class</th><th align="center" colspan="2" rowspan="1">Allele Frequency (%)</th></tr><tr><th align="center" rowspan="1" colspan="1">NI</th><th align="center" rowspan="1" colspan="1">CFTR2</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">F508del</td><td align="left" rowspan="1" colspan="1">c.1521_1523delCTT</td><td align="left" rowspan="1" colspan="1">p.Phe508del</td><td align="left" rowspan="1" colspan="1">Deletion, CFTR protein abnormal and destroyed by cell before reaching cell membrane</td><td align="center" rowspan="1" colspan="1">CF causing</td><td align="center" rowspan="1" colspan="1">II</td><td align="center" rowspan="1" colspan="1">62.29</td><td align="center" rowspan="1" colspan="1">73.08</td></tr><tr><td align="left" rowspan="1" colspan="1">R117H</td><td align="left" rowspan="1" colspan="1">c.350G&gt;A</td><td align="left" rowspan="1" colspan="1">p.Argl 17His</td><td align="left" rowspan="1" colspan="1">Missense mutation, CFTR protein reaches cell membrane but channel does not move chloride effectively</td><td align="center" rowspan="1" colspan="1">Varying clinical conse-quence</td><td align="center" rowspan="1" colspan="1">IV</td><td align="center" rowspan="1" colspan="1">8.86</td><td align="center" rowspan="1" colspan="1">2.04</td></tr><tr><td align="left" rowspan="1" colspan="1">G551D</td><td align="left" rowspan="1" colspan="1">c.1652G&gt;A</td><td align="left" rowspan="1" colspan="1">p.Gly551Asp</td><td align="left" rowspan="1" colspan="1">Substitution, CFTR protein reaches cell membrane but channel is blocked</td><td align="center" rowspan="1" colspan="1">CF causing</td><td align="center" rowspan="1" colspan="1">III</td><td align="center" rowspan="1" colspan="1">4.98</td><td align="center" rowspan="1" colspan="1">3.28</td></tr><tr><td align="left" rowspan="1" colspan="1">G542X</td><td align="left" rowspan="1" colspan="1">c.1624G&gt;T</td><td align="left" rowspan="1" colspan="1">p.Gly542X</td><td align="left" rowspan="1" colspan="1">Nonsense, no functional CFTR protein made</td><td align="center" rowspan="1" colspan="1">CF causing</td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">3.28</td><td align="center" rowspan="1" colspan="1">3.92</td></tr><tr><td align="left" rowspan="1" colspan="1">R560T</td><td align="left" rowspan="1" colspan="1">c.1679G&gt;C</td><td align="left" rowspan="1" colspan="1">p.Arg560Thr</td><td align="left" rowspan="1" colspan="1">CFTR protein abnormal and destroyed by cell before reaching cell membrane</td><td align="center" rowspan="1" colspan="1">CF causing</td><td align="center" rowspan="1" colspan="1">II</td><td align="center" rowspan="1" colspan="1">2.79</td><td align="center" rowspan="1" colspan="1">0.38</td></tr><tr><td align="left" rowspan="1" colspan="1">P67L</td><td align="left" rowspan="1" colspan="1">c.200C&gt;T</td><td align="left" rowspan="1" colspan="1">p.Pro67Leu</td><td align="left" rowspan="1" colspan="1">CFTR protein abnormal and destroyed by cell before reaching cell membrane</td><td align="center" rowspan="1" colspan="1">CF causing</td><td align="center" rowspan="1" colspan="1">II</td><td align="center" rowspan="1" colspan="1">2.19</td><td align="center" rowspan="1" colspan="1">0.27</td></tr><tr><td align="left" rowspan="1" colspan="1">1078delT</td><td align="left" rowspan="1" colspan="1">c.948delT</td><td align="left" rowspan="1" colspan="1">p.Phe316LeufsX12</td><td align="left" rowspan="1" colspan="1">No functional CFTR protein made</td><td align="center" rowspan="1" colspan="1">CF causing</td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">&lt;2.0%</td><td align="center" rowspan="1" colspan="1">0.21</td></tr><tr><td align="left" rowspan="1" colspan="1">1154insTC</td><td align="left" rowspan="1" colspan="1">c. 1021 _1022du pT C</td><td align="left" rowspan="1" colspan="1">p.Phe342HisfsTer28</td><td align="left" rowspan="1" colspan="1">No functional CFTR protein made</td><td align="center" rowspan="1" colspan="1">CF causing</td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">&lt;2.0%</td><td align="center" rowspan="1" colspan="1">0.24</td></tr><tr><td align="left" rowspan="1" colspan="1">1248+2T-&gt;A</td><td align="left" rowspan="1" colspan="1">C.1116+1G&gt;A</td><td align="left" rowspan="1" colspan="1">No protein name</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">CF causing</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&lt;2.0%</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">1461ins4</td><td align="left" rowspan="1" colspan="1">c.1327_1330dupGATA / c.1326_1329dupAGAT / c. 1329_1330insAGAT</td><td align="left" rowspan="1" colspan="1">p.lle444ArgfsX3</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">CF causing</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&lt;2.0%</td><td align="center" rowspan="1" colspan="1">0.06</td></tr><tr><td align="left" rowspan="1" colspan="1">1717-1G-&gt;A</td><td align="left" rowspan="1" colspan="1">c.1585-1 G&gt;A</td><td align="left" rowspan="1" colspan="1">No protein name</td><td align="left" rowspan="1" colspan="1">No functional CFTR protein made</td><td align="center" rowspan="1" colspan="1">CF causing</td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">&lt;2.0%</td><td align="center" rowspan="1" colspan="1">1.35</td></tr><tr><td align="left" rowspan="1" colspan="1">1898+1 G-&gt;A</td><td align="left" rowspan="1" colspan="1">c.1766+1 G&gt;A</td><td align="left" rowspan="1" colspan="1">No protein name</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">CF causing</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&lt;2.0%</td><td align="center" rowspan="1" colspan="1">0.47</td></tr><tr><td align="left" rowspan="1" colspan="1">2184insA / 2185insA</td><td align="left" rowspan="1" colspan="1">c.2052dupA / c.2052_2053insA</td><td align="left" rowspan="1" colspan="1">p.Gin685ThrfsX4</td><td align="left" rowspan="1" colspan="1">Insertion, no functional CFTR protein made</td><td align="center" rowspan="1" colspan="1">CF causing</td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">&lt;2.0%</td><td align="center" rowspan="1" colspan="1">0.36</td></tr><tr><td align="left" rowspan="1" colspan="1">2751+2T-&gt;C</td><td align="left" rowspan="1" colspan="1">c.2619+2T&gt;C</td><td align="left" rowspan="1" colspan="1">No protein name</td><td align="left" rowspan="1" colspan="1">Splicing mutation</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&lt;2.0%</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">2789+2insA</td><td align="left" rowspan="1" colspan="1">c.2657+2_2657+3insA</td><td align="left" rowspan="1" colspan="1">No protein name</td><td align="left" rowspan="1" colspan="1">Insertion</td><td align="center" rowspan="1" colspan="1">Unknown significance</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&lt;2.0%</td><td align="center" rowspan="1" colspan="1">0.09</td></tr><tr><td align="left" rowspan="1" colspan="1">2789+5G-&gt;A</td><td align="left" rowspan="1" colspan="1">c.2657+5G&gt;A</td><td align="left" rowspan="1" colspan="1">No protein name</td><td align="left" rowspan="1" colspan="1">Substitution, CFTR protein made and works but quantity is insufficient</td><td align="center" rowspan="1" colspan="1">CF causing</td><td align="center" rowspan="1" colspan="1">V</td><td align="center" rowspan="1" colspan="1">&lt;2.0%</td><td align="center" rowspan="1" colspan="1">1.11</td></tr><tr><td align="left" rowspan="1" colspan="1">3120G-&gt;A/Q996Q</td><td align="left" rowspan="1" colspan="1">c.2988G&gt;A</td><td align="left" rowspan="1" colspan="1">p.Gln996Gln996</td><td align="left" rowspan="1" colspan="1">CFTR protein made and works but quantity is insufficient</td><td align="center" rowspan="1" colspan="1">CF causing</td><td align="center" rowspan="1" colspan="1">V</td><td align="center" rowspan="1" colspan="1">&lt;2.0%</td><td align="center" rowspan="1" colspan="1">0.09</td></tr><tr><td align="left" rowspan="1" colspan="1">3272-26A-&gt;G</td><td align="left" rowspan="1" colspan="1">c.3140-26A&gt;G</td><td align="left" rowspan="1" colspan="1">No protein name</td><td align="left" rowspan="1" colspan="1">CFTR protein made and works but quantity is insufficient</td><td align="center" rowspan="1" colspan="1">CF causing</td><td align="center" rowspan="1" colspan="1">V</td><td align="center" rowspan="1" colspan="1">&lt;2.0%</td><td align="center" rowspan="1" colspan="1">0.52</td></tr><tr><td align="left" rowspan="1" colspan="1">3659delC</td><td align="left" rowspan="1" colspan="1">c.3528delC</td><td align="left" rowspan="1" colspan="1">p.Lys1177SerfsX15</td><td align="left" rowspan="1" colspan="1">No functional CFTR protein made</td><td align="center" rowspan="1" colspan="1">CF causing</td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">&lt;2.0%</td><td align="center" rowspan="1" colspan="1">0.59</td></tr><tr><td align="left" rowspan="1" colspan="1">3849+1OkbC-&gt;T</td><td align="left" rowspan="1" colspan="1">c.3718-2477C&gt;T, C.3717+10kbC&gt;T, c.3717+12191C&gt;T</td><td align="left" rowspan="1" colspan="1">No protein name</td><td align="left" rowspan="1" colspan="1">CFTR protein made and works but quantity is insufficient</td><td align="center" rowspan="1" colspan="1">CF causing</td><td align="center" rowspan="1" colspan="1">V</td><td align="center" rowspan="1" colspan="1">&lt;2.0%</td><td align="center" rowspan="1" colspan="1">1.24</td></tr><tr><td align="left" rowspan="1" colspan="1">3850-1 G-&gt;A</td><td align="left" rowspan="1" colspan="1">c.3718-1G&gt;A</td><td align="left" rowspan="1" colspan="1">No protein name</td><td align="left" rowspan="1" colspan="1">mRNA splicing defect, CFTR protein made and works but quantity is insufficient</td><td align="center" rowspan="1" colspan="1">CF causing</td><td align="center" rowspan="1" colspan="1">V</td><td align="center" rowspan="1" colspan="1">&lt;2.0%</td><td align="center" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">5T</td><td align="left" rowspan="1" colspan="1">C.1210-12T[5]</td><td align="left" rowspan="1" colspan="1">No protein name</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Varying clinical conse-quence</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&lt;2.0%</td><td align="center" rowspan="1" colspan="1">0.56</td></tr><tr><td align="left" rowspan="1" colspan="1">5T;TG12</td><td align="left" rowspan="1" colspan="1">c.1210-33 1210-6GT[12] T[4]</td><td align="left" rowspan="1" colspan="1">No protein name</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">CF causing</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&lt;2.0%</td><td align="center" rowspan="1" colspan="1">0.2</td></tr><tr><td align="left" rowspan="1" colspan="1">5&#8217;UTR to exon 9</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&lt;2.0%</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">621+1G-&gt;T</td><td align="left" rowspan="1" colspan="1">c.489+1 G&gt;T</td><td align="left" rowspan="1" colspan="1">No protein name</td><td align="left" rowspan="1" colspan="1">mRNA splicing defect, no functional CFTR protein made</td><td align="center" rowspan="1" colspan="1">CF causing</td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">&lt;2.0%</td><td align="center" rowspan="1" colspan="1">1.45</td></tr><tr><td align="left" rowspan="1" colspan="1">711+2T-&gt;C</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&lt;2.0%</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">711+3A-&gt;G</td><td align="left" rowspan="1" colspan="1">c.579+3A&gt;G</td><td align="left" rowspan="1" colspan="1">No protein name</td><td align="left" rowspan="1" colspan="1">mRNA splicing defect, CFTR protein made and works but quantity is insufficient</td><td align="center" rowspan="1" colspan="1">Varying clinical conse-quence</td><td align="center" rowspan="1" colspan="1">V</td><td align="center" rowspan="1" colspan="1">&lt;2.0%</td><td align="center" rowspan="1" colspan="1">0.07</td></tr><tr><td align="left" rowspan="1" colspan="1">A349V</td><td align="left" rowspan="1" colspan="1">c.1046C&gt;T</td><td align="left" rowspan="1" colspan="1">p.(Ala349Val)</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Unknown significance</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&lt;2.0%</td><td align="center" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">D1152H</td><td align="left" rowspan="1" colspan="1">c.3454G&gt;C</td><td align="left" rowspan="1" colspan="1">p.AspI 152H&#205;S</td><td align="left" rowspan="1" colspan="1">CFTR protein reaches cell membrane but channel does not move chloride effectively</td><td align="center" rowspan="1" colspan="1">Varying clinical conse-quence</td><td align="center" rowspan="1" colspan="1">IV</td><td align="center" rowspan="1" colspan="1">&lt;2.0%</td><td align="center" rowspan="1" colspan="1">0.62</td></tr><tr><td align="left" rowspan="1" colspan="1">E60X</td><td align="left" rowspan="1" colspan="1">c.178G&gt;T</td><td align="left" rowspan="1" colspan="1">p.Giu60Ter</td><td align="left" rowspan="1" colspan="1">Nonsense</td><td align="center" rowspan="1" colspan="1">CF causing</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&lt;2.0%</td><td align="center" rowspan="1" colspan="1">0.33</td></tr><tr><td align="left" rowspan="1" colspan="1">F508C</td><td align="left" rowspan="1" colspan="1">c.1523T&gt;G</td><td align="left" rowspan="1" colspan="1">p.Phe508Cys</td><td align="left" rowspan="1" colspan="1">Substitution</td><td align="center" rowspan="1" colspan="1">Varying clinical conse-quence</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&lt;2.0%</td><td align="center" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">G576A</td><td align="left" rowspan="1" colspan="1">c.1727G&gt;C</td><td align="left" rowspan="1" colspan="1">p.Giy576Aia</td><td align="left" rowspan="1" colspan="1">CFTR protein reaches cell membrane but channel does not move chloride effectively</td><td align="center" rowspan="1" colspan="1">Non CF causing</td><td align="center" rowspan="1" colspan="1">IV</td><td align="center" rowspan="1" colspan="1">&lt;2.0%</td><td align="center" rowspan="1" colspan="1">0.08</td></tr><tr><td align="left" rowspan="1" colspan="1">G85E</td><td align="left" rowspan="1" colspan="1">c.254G&gt;A</td><td align="left" rowspan="1" colspan="1">p.Giy85Giu</td><td align="left" rowspan="1" colspan="1">Missense, substitution, CFTR protein abnormal and destroyed by cell before reaching cell membrane</td><td align="center" rowspan="1" colspan="1">CF causing</td><td align="center" rowspan="1" colspan="1">II</td><td align="center" rowspan="1" colspan="1">&lt;2.0%</td><td align="center" rowspan="1" colspan="1">0.66</td></tr><tr><td align="left" rowspan="1" colspan="1">I37R</td><td align="left" rowspan="1" colspan="1">c.110T&gt;G</td><td align="left" rowspan="1" colspan="1">p.ile37Arg</td><td align="left" rowspan="1" colspan="1">Missense, CFTR protein reaches cell membrane but channel is blocked</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">III</td><td align="center" rowspan="1" colspan="1">&lt;2.0%</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">I507del</td><td align="left" rowspan="1" colspan="1">c.1519_1521delATC</td><td align="left" rowspan="1" colspan="1">p.iie507del</td><td align="left" rowspan="1" colspan="1">CFTR protein abnormal and destroyed by cell before reaching cell membrane</td><td align="center" rowspan="1" colspan="1">CF causing</td><td align="center" rowspan="1" colspan="1">II</td><td align="center" rowspan="1" colspan="1">&lt;2.0%</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">L206W</td><td align="left" rowspan="1" colspan="1">C.617T&gt;G</td><td align="left" rowspan="1" colspan="1">p.Leu206Trp</td><td align="left" rowspan="1" colspan="1">CFTR protein abnormal and destroyed by cell before reaching cell membrane/CFTR protein reaches cell membrane but channel is blocked</td><td align="center" rowspan="1" colspan="1">CF causing</td><td align="center" rowspan="1" colspan="1">II-III</td><td align="center" rowspan="1" colspan="1">&lt;2.0%</td><td align="center" rowspan="1" colspan="1">0.37</td></tr><tr><td align="left" rowspan="1" colspan="1">L967S</td><td align="left" rowspan="1" colspan="1">c.2900T&gt;C</td><td align="left" rowspan="1" colspan="1">p.(Leu967Ser)</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Varying clinical conse-quence</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&lt;2.0%</td><td align="center" rowspan="1" colspan="1">0.02</td></tr><tr><td align="left" rowspan="1" colspan="1">M1210K</td><td align="left" rowspan="1" colspan="1">c.3629T&gt;A</td><td align="left" rowspan="1" colspan="1">p.Met1210Lys</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">CF causing</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&lt;2.0%</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">N1303K</td><td align="left" rowspan="1" colspan="1">c.3909C&gt;G</td><td align="left" rowspan="1" colspan="1">p.Asn1303Lys</td><td align="left" rowspan="1" colspan="1">Missense / CFTR protein reaches cell membrane but channel is blocked</td><td align="center" rowspan="1" colspan="1">CF causing</td><td align="center" rowspan="1" colspan="1">II</td><td align="center" rowspan="1" colspan="1">&lt;2.0%</td><td align="center" rowspan="1" colspan="1">2.41</td></tr><tr><td align="left" rowspan="1" colspan="1">No legacy name</td><td align="left" rowspan="1" colspan="1">c.4035_4038dup</td><td align="left" rowspan="1" colspan="1">p.S1347Pfs*13</td><td align="left" rowspan="1" colspan="1">Protein change</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&lt;2.0%</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">No legacy name</td><td align="left" rowspan="1" colspan="1">c.869+1 G&gt;C</td><td align="left" rowspan="1" colspan="1">No protein name</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">CF causing</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&lt;2.0%</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Q493X</td><td align="left" rowspan="1" colspan="1">c.1477C&gt;T</td><td align="left" rowspan="1" colspan="1">p.Gln493Ter</td><td align="left" rowspan="1" colspan="1">Nonsense, no functional CFTR protein made</td><td align="center" rowspan="1" colspan="1">CF causing</td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">&lt;2.0%</td><td align="center" rowspan="1" colspan="1">0.32</td></tr><tr><td align="left" rowspan="1" colspan="1">R1070P</td><td align="left" rowspan="1" colspan="1">c.3209G&gt;C</td><td align="left" rowspan="1" colspan="1">p.(Arg1070Pro)</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&lt;2.0%</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">R1070W</td><td align="left" rowspan="1" colspan="1">c.3208C&gt;T</td><td align="left" rowspan="1" colspan="1">p.Arg1070Trp</td><td align="left" rowspan="1" colspan="1">Missense, CFTR protein abnormal and destroyed by cell before reaching cell membrane/CFTR protein reaches cell membrane but channel is blocked</td><td align="center" rowspan="1" colspan="1">Varying clinical conse-quence</td><td align="center" rowspan="1" colspan="1">ll/lll</td><td align="center" rowspan="1" colspan="1">&lt;2.0%</td><td align="center" rowspan="1" colspan="1">0.04</td></tr><tr><td align="left" rowspan="1" colspan="1">R1158X</td><td align="left" rowspan="1" colspan="1">c.3472C&gt;T</td><td align="left" rowspan="1" colspan="1">p.Arg1158Ter</td><td align="left" rowspan="1" colspan="1">Nonsense, no functional CFTR protein made</td><td align="center" rowspan="1" colspan="1">CF causing</td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">&lt;2.0%</td><td align="center" rowspan="1" colspan="1">0.19</td></tr><tr><td align="left" rowspan="1" colspan="1">R1162X</td><td align="left" rowspan="1" colspan="1">c.3484C&gt;T</td><td align="left" rowspan="1" colspan="1">p.Argl 162X</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">CF causing</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&lt;2.0%</td><td align="center" rowspan="1" colspan="1">0.69</td></tr><tr><td align="left" rowspan="1" colspan="1">R1239R/3849G-&gt;A</td><td align="left" rowspan="1" colspan="1">c.3717G&gt;A</td><td align="left" rowspan="1" colspan="1">p.Arg1239Arg</td><td align="left" rowspan="1" colspan="1">Abnormal splicing</td><td align="center" rowspan="1" colspan="1">CF causing</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&lt;2.0%</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">R134S</td><td align="left" rowspan="1" colspan="1">c.402F&gt;T</td><td align="left" rowspan="1" colspan="1">p.(Arg134Ser)</td><td align="left" rowspan="1" colspan="1">Missense</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&lt;2.0%</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">R297Q</td><td align="left" rowspan="1" colspan="1">c.890G&gt;A</td><td align="left" rowspan="1" colspan="1">p.Arg297Gln</td><td align="left" rowspan="1" colspan="1">Substitution, missense</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&lt;2.0%</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">R334Q</td><td align="left" rowspan="1" colspan="1">C.1001 G&gt;A</td><td align="left" rowspan="1" colspan="1">p.Arg334Gln</td><td align="left" rowspan="1" colspan="1">Missense</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&lt;2.0%</td><td align="center" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">R347H</td><td align="left" rowspan="1" colspan="1">c.1040G&gt;A</td><td align="left" rowspan="1" colspan="1">p.Arg347His</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">CF causing</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&lt;2.0%</td><td align="center" rowspan="1" colspan="1">0.22</td></tr><tr><td align="left" rowspan="1" colspan="1">R352Q</td><td align="left" rowspan="1" colspan="1">c.1055G&gt;A</td><td align="left" rowspan="1" colspan="1">p.Arg352Gln</td><td align="left" rowspan="1" colspan="1">CFTR protein reaches cell membrane but channel is blocked</td><td align="center" rowspan="1" colspan="1">CF causing</td><td align="center" rowspan="1" colspan="1">III</td><td align="center" rowspan="1" colspan="1">&lt;2.0%</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">R751L</td><td align="left" rowspan="1" colspan="1">c.2252G&gt;T</td><td align="left" rowspan="1" colspan="1">p.Arg751 Leu</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&lt;2.0%</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">S1159P</td><td align="left" rowspan="1" colspan="1">c.3475T&gt;C</td><td align="left" rowspan="1" colspan="1">p.Ser1159Pro</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">CF causing</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&lt;2.0%</td><td align="center" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">S549N</td><td align="left" rowspan="1" colspan="1">c.1646G&gt;A</td><td align="left" rowspan="1" colspan="1">p.Ser549Asn</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">CF causing</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&lt;2.0%</td><td align="center" rowspan="1" colspan="1">0.21</td></tr><tr><td align="left" rowspan="1" colspan="1">TG12T5</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CFTR protein reaches cell membrane but channel does not move chloride effectively/CFTR protein made and works but quantity is insufficient</td><td align="center" rowspan="1" colspan="1">CF causing</td><td align="center" rowspan="1" colspan="1">IV/V</td><td align="center" rowspan="1" colspan="1">&lt;2.0%</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">V520F</td><td align="left" rowspan="1" colspan="1">c.1558G&gt;T</td><td align="left" rowspan="1" colspan="1">p.Val520Phe</td><td align="left" rowspan="1" colspan="1">CFTR protein abnormal and destroyed by cell before reaching cell membrane</td><td align="center" rowspan="1" colspan="1">CF causing</td><td align="center" rowspan="1" colspan="1">II</td><td align="center" rowspan="1" colspan="1">&lt;2.0%</td><td align="center" rowspan="1" colspan="1">0.17</td></tr><tr><td align="left" rowspan="1" colspan="1">W1282X</td><td align="left" rowspan="1" colspan="1">c.3846G&gt;A</td><td align="left" rowspan="1" colspan="1">p.Trp1282X</td><td align="left" rowspan="1" colspan="1">Nonsense, no functional CFTR protein made</td><td align="center" rowspan="1" colspan="1">CF causing</td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">&lt;2.0%</td><td align="center" rowspan="1" colspan="1">1.75</td></tr><tr><td align="left" rowspan="1" colspan="1">W361R</td><td align="left" rowspan="1" colspan="1">c.1081T&gt;C</td><td align="left" rowspan="1" colspan="1">p.Trp361Arg</td><td align="left" rowspan="1" colspan="1">Missense</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&lt;2.0%</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Y1092H</td><td align="left" rowspan="1" colspan="1">c.3274T&gt;C</td><td align="left" rowspan="1" colspan="1">p.Tyr1092His</td><td align="left" rowspan="1" colspan="1">Substitution, missense</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&lt;2.0%</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Y1092X</td><td align="left" rowspan="1" colspan="1">c.3276C&gt;A / c.3276C&gt;G</td><td align="left" rowspan="1" colspan="1">p.Tyr1092X</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">CF causing</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&lt;2.0%</td><td align="center" rowspan="1" colspan="1">0.25</td></tr><tr><td align="left" rowspan="1" colspan="1">Y563N</td><td align="left" rowspan="1" colspan="1">c.1687T&gt;A</td><td align="left" rowspan="1" colspan="1">p.Tyr563Asn</td><td align="left" rowspan="1" colspan="1">Missense, CFTR protein reaches cell membrane but channel is blocked</td><td align="center" rowspan="1" colspan="1">CF causing</td><td align="center" rowspan="1" colspan="1">III</td><td align="center" rowspan="1" colspan="1">&lt;2.0%</td><td align="center" rowspan="1" colspan="1">0.04</td></tr></tbody></table><table-wrap-foot><fn id="tn1"><p>The six most frequently occurring alleles are listed in descending order. The remaining alleles (&lt;2% frequency) are listed in alphabetical order.</p></fn></table-wrap-foot></table-wrap><p>Northern Ireland CF alleles are shown along with CFTR2 database mutation frequencies. Total number of mutations in the CFTR2 database was 89052, as of 2021. The countries that make up this data base are Australia (n=3,414), Belgium (n=1,281), Brazil (n=1,211), Bulgaria (n=16), Canada (n=5328), Chile (n=27), Cyprus (n=42), Czech Republic (n=629), The European CF Society [Austria, Denmark, Germany, Greece, Hungary, Israel, Italy, Latvia, Portugal, Moldova, Russia, Serbia, Slovakia, Slovenia, Spain, Sweden &amp; Switzerland] (n=16,124), Estonia (n=49), France (n=1,986), Ireland (n=1,083), Japan (n=15), Lithuania (n=22), Macedonia (n=109), Mexico (n=121), The Netherlands (n=1,453), Palestine (n=33), Republika Srpska (n=16), Saudi Arabia (n=&lt;10), South Africa (n=155), South Korea (n=&lt;10), Turkey (n=282), UK (n=9,421), US (n=46,183), Ukraine (n=31) and Venezuela (n=&lt;10). Some mutations identified were not found in the CFTR2 database which contains 466 listed mutations, but not all known variants, as some are found in only a few individuals worldwide and some information on class category is missing as CFTR2 only contains information on the 322 most common variants. Over 1,300 alleles have been reported as CF causing, with other less common alleles putative effects unknown.<xref rid="b12" ref-type="bibr">12</xref></p><p><xref rid="t03" ref-type="table">Table 3</xref> compares the frequency of F508del homozygous, F508del heterozygous and others within the countries of the British Isles, as well as with a further eight countries. F508del prevalence varies globally and despite geographical proximity, differs markedly in Northern Ireland compared to Ireland and Great Britain. Northern Ireland has the highest frequency of F508del heterozygous and lowest F508del homozygous frequency, from the European countries shown. F508del is the most common allele in all countries analysed and has a higher frequency in Europe, USA, South Africa, and Canada than in Northern Ireland and a lower frequency in South America and Asia. Other non-F508del mutations increase in frequency in India, Iran, and Brazil. <xref rid="f02" ref-type="fig">Figure 2</xref> shows a comparison of the four most common CFTR alleles identified in the Northern Ireland CF population with other global regions. <xref rid="t04" ref-type="table">Table 4</xref> compares the CFTR mutations described in the Northern Ireland population previously in 1996 with those described in the Northern Ireland CF population from 2021. <xref rid="f03" ref-type="fig">Figure 3A</xref> shows the prevalence of CFTR mutations by year of birth, <xref rid="f04" ref-type="fig">Figure 3B</xref> shows the frequency of F508del mutations by age and <xref rid="f05" ref-type="fig">Figure 3C</xref> shows the frequency of F508del mutations in 2021 by frequency in the Northern Ireland adult and paediatric CF populations. <xref rid="f06" ref-type="fig">Figure 4</xref> compares the six most common CFTR mutations in Northern Ireland in 1996 and 2021.</p><table-wrap position="float" id="t03" orientation="portrait"><label>Table 3:</label><caption><title>Comparison of the prevalence of the F508del mutation in Northern Ireland with other countries within the British Isles and globally.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Genotype Country</th><th align="left" rowspan="1" colspan="1">F508del homozygous (%)</th><th align="left" rowspan="1" colspan="1">F508del heterozygous (%)</th><th align="left" rowspan="1" colspan="1">Other (includes missing or inconclusive) (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">NI</td><td align="left" rowspan="1" colspan="1">34.2</td><td align="left" rowspan="1" colspan="1">51.5</td><td align="left" rowspan="1" colspan="1">14.2</td></tr><tr><td align="left" rowspan="1" colspan="1">Ireland</td><td align="left" rowspan="1" colspan="1">55.5</td><td align="left" rowspan="1" colspan="1">36.5</td><td align="left" rowspan="1" colspan="1">8.0</td></tr><tr><td align="left" rowspan="1" colspan="1">England</td><td align="left" rowspan="1" colspan="1">49.2</td><td align="left" rowspan="1" colspan="1">40.0</td><td align="left" rowspan="1" colspan="1">10.8</td></tr><tr><td align="left" rowspan="1" colspan="1">Scotland</td><td align="left" rowspan="1" colspan="1">42.1</td><td align="left" rowspan="1" colspan="1">47.6</td><td align="left" rowspan="1" colspan="1">10.3</td></tr><tr><td align="left" rowspan="1" colspan="1">Wales</td><td align="left" rowspan="1" colspan="1">44.2</td><td align="left" rowspan="1" colspan="1">45.0</td><td align="left" rowspan="1" colspan="1">10.8</td></tr><tr><td align="left" rowspan="1" colspan="1">Netherlands</td><td align="left" rowspan="1" colspan="1">55.5</td><td align="left" rowspan="1" colspan="1">35.3</td><td align="left" rowspan="1" colspan="1">9.2</td></tr><tr><td align="left" rowspan="1" colspan="1">France</td><td align="left" rowspan="1" colspan="1">41.4</td><td align="left" rowspan="1" colspan="1">41.2</td><td align="left" rowspan="1" colspan="1">17.4</td></tr><tr><td align="left" rowspan="1" colspan="1">Australia</td><td align="left" rowspan="1" colspan="1">47.2</td><td align="left" rowspan="1" colspan="1">40.5</td><td align="left" rowspan="1" colspan="1">12.4</td></tr><tr><td align="left" rowspan="1" colspan="1">USA</td><td align="left" rowspan="1" colspan="1">44.5</td><td align="left" rowspan="1" colspan="1">41.2</td><td align="left" rowspan="1" colspan="1">14.2</td></tr><tr><td align="left" rowspan="1" colspan="1">Canada</td><td align="left" rowspan="1" colspan="1">47.2</td><td align="left" rowspan="1" colspan="1">40.5</td><td align="left" rowspan="1" colspan="1">12.4</td></tr><tr><td align="left" rowspan="1" colspan="1">Brazil</td><td align="left" rowspan="1" colspan="1">23.9</td><td align="left" rowspan="1" colspan="1">27.5</td><td align="left" rowspan="1" colspan="1">48.6</td></tr><tr><td align="left" rowspan="1" colspan="1">Belgium</td><td align="left" rowspan="1" colspan="1">45.8</td><td align="left" rowspan="1" colspan="1">38.3</td><td align="left" rowspan="1" colspan="1">15.9</td></tr><tr><td align="left" rowspan="1" colspan="1">South Africa</td><td align="left" rowspan="1" colspan="1">47.0</td><td align="left" rowspan="1" colspan="1">33.0</td><td align="left" rowspan="1" colspan="1">20.0</td></tr></tbody></table><table-wrap-foot><fn id="tn2"><p><bold>Footnote:</bold> Data sourced from international cystic fibrosis registries as detailed in <bold><xref rid="t01" ref-type="table">Table 1</xref></bold>.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="t04" orientation="portrait"><label>Table 4:</label><caption><title>Comparison of the CFTR mutations described in the Northern Ireland population previously in 1996 with those described in the Northern Ireland CF population from 2021.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" rowspan="1" colspan="1">CFTR mutation in 1996</th><th align="center" rowspan="1" colspan="1">Shared CFTR mutations (1996 &amp; 2021)</th><th align="center" rowspan="1" colspan="1">CFTR mutations in 2021</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">3849 G&gt;A</td><td align="left" rowspan="1" colspan="1">1154insTC</td><td align="left" rowspan="1" colspan="1">1078delT</td></tr><tr><td align="left" rowspan="1" colspan="1">557delT</td><td align="left" rowspan="1" colspan="1">2789+5G-&gt;A</td><td align="left" rowspan="1" colspan="1">1248+2T-&gt;A</td></tr><tr><td align="left" rowspan="1" colspan="1">MIL G&gt;T</td><td align="left" rowspan="1" colspan="1">3120G-&gt;A/Q996Q</td><td align="left" rowspan="1" colspan="1">1461ins4</td></tr><tr><td align="left" rowspan="1" colspan="1">Q2X</td><td align="left" rowspan="1" colspan="1">3659delC</td><td align="left" rowspan="1" colspan="1">1717-1G-&gt;A</td></tr><tr><td align="left" rowspan="1" colspan="1">V562L</td><td align="left" rowspan="1" colspan="1">3849+10kbC-&gt;T</td><td align="left" rowspan="1" colspan="1">1898+1G-&gt;A</td></tr><tr><td align="left" rowspan="1" colspan="1">Y917C</td><td align="left" rowspan="1" colspan="1">3850-1G-&gt;A</td><td align="left" rowspan="1" colspan="1">2184insA / 2185insA</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">621+1G-&gt;T</td><td align="left" rowspan="1" colspan="1">2751+2T-&gt;C</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">711+3A-&gt;G</td><td align="left" rowspan="1" colspan="1">2789+2insA</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">E60X</td><td align="left" rowspan="1" colspan="1">3272-26A-&gt;G</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">F508del</td><td align="left" rowspan="1" colspan="1">5T</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">G542X</td><td align="left" rowspan="1" colspan="1">5T;TG12</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">G551D</td><td align="left" rowspan="1" colspan="1">5&#8217;UTR to exon 9</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">I507del</td><td align="left" rowspan="1" colspan="1">711+2T-&gt;C</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">L206W</td><td align="left" rowspan="1" colspan="1">A349V</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">N1303K</td><td align="left" rowspan="1" colspan="1">D1152H</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">P67L</td><td align="left" rowspan="1" colspan="1">F508C</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">R1162X</td><td align="left" rowspan="1" colspan="1">G576A</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">R117H</td><td align="left" rowspan="1" colspan="1">G85E</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">R297Q</td><td align="left" rowspan="1" colspan="1">I37R</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">R560T</td><td align="left" rowspan="1" colspan="1">L967S</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">V520F</td><td align="left" rowspan="1" colspan="1">M1210K</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">W1282X</td><td align="left" rowspan="1" colspan="1">No legacy name (c.4035_4038dup)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Y563N</td><td align="left" rowspan="1" colspan="1">No legacy name (c.869+1G&gt;C)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Q493X</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">R1070P</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">R1070W</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">R1158X</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">R1239R/3849G-&gt;A</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">R134S</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">R334Q</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">R347H</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">R352Q</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">R751L</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">S1159P</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">S549N</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">TG12T5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">W361R</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Y1092H</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Y1092X</td></tr></tbody></table><table-wrap-foot><fn id="tn3"><p><bold>Footnote:</bold> Data sources: 2021- current study; 1996<xref rid="b11" ref-type="bibr">11</xref></p></fn></table-wrap-foot></table-wrap><fig position="float" id="f02" orientation="portrait"><label>Figure 2:</label><caption><title>Comparison of the four most common CFTR alleles identified in the Northern Ireland CF population with other global regions.</title><p><bold>Footnote:</bold> Data sourced from international cystic fibrosis registries as detailed in <xref rid="t01" ref-type="table">Table 1</xref>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="umj-94-2-64-g002.jpg"/></fig><fig position="float" id="f03" orientation="portrait"><label>Figure 3:</label><caption><title><bold>A</bold> Frequency of CFTR alleles (&gt;4) in the Northern Ireland CF population (adults and paediatrics) relative to year-of-birth CFTR, cystic fibrosis transmembrane conductance regulator</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="umj-94-2-64-g003.jpg"/></fig><fig position="float" id="f04" orientation="portrait"><label>Figure 3:</label><caption><title><bold>B</bold> Frequency of CFTR mutation groups in relation to current age of the Northern Ireland CF population. CFTR, cystic fibrosis transmembrane conductance regulator</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="umj-94-2-64-g004.jpg"/></fig><fig position="float" id="f05" orientation="portrait"><label>Figure 3:</label><caption><title><bold>C</bold> F508del distribution within the Northern Ireland adult and paediatric CF populations</title><p><bold>Footnote:</bold> &#8220;Key: Blue F508del homozygous; Orange F508del heterozygous; Grey Others&#8221;</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="umj-94-2-64-g005.jpg"/></fig><fig position="float" id="f06" orientation="portrait"><label>Figure 4:</label><caption><title>Comparison of the six most common CFTR mutations in the Northern Ireland CF population in 1996 and 2021</title><p><bold>Footnote:</bold> Data sources: 2021- current study; 1996<xref rid="b11" ref-type="bibr">11</xref></p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="umj-94-2-64-g006.jpg"/></fig></sec><sec sec-type="discussion"><title>Discussion:</title><sec><title>CFTR allele epidemiology in paediatric and adult CF populations in Northern Ireland</title><p>Northern Ireland&#8217;s CF epidemiological profile and gene pool has changed considerably with time, as illustrated in <xref rid="f03" ref-type="fig">Figure 3A</xref>, <xref rid="f04" ref-type="fig">Figure 3B</xref> and <xref rid="f06" ref-type="fig">Figure 4</xref>. Allelic variation and individuals per year-group has increased steadily from 1980, with greater mutation variation in younger groups contributing to historic gene pool dilution and diversification, reflecting improved life expectancy. Increased diversity aligns with the end of &#8220;The Troubles&#8221; in 1998, where increasing immigration could have potentially resulted in allelic diversity and vertical passing of different variants. Between 2000-2010, almost 122,000 people immigrated to Northern Ireland,<xref rid="b13" ref-type="bibr">13</xref> potentially introducing different mutations into Northern Ireland&#8217;s CF gene pool. Most immigrants were from Eastern Europe, potentially explaining N1303K&#8217;s increase from 1.18% at its first appearance in 1980&#8217;s to 2.61% after 2010, as this allele is the third most common in the Lithuanian CF population.<xref rid="b14" ref-type="bibr">14</xref> 3849+10kbC-&gt;T and G542X are noted in the CF population after 1990, most frequent in Lithuania and Latvia respectively.<xref rid="b15" ref-type="bibr">15</xref> 3120+1G-&gt;T is noted in the current Northern Ireland CF population born after 1980 and is predominantly an African variant.<xref rid="b16" ref-type="bibr">16</xref> Although historically predominately a Caucasian disease, from 20102020, the percentage of Indian, Pakistani, African, and other ethnicities with CF have risen in the UK, possibly due to improved diagnosis.<xref rid="b17" ref-type="bibr">17</xref> Additionally, improvements in molecular analyses, particularly sequencing, may have concurrently aided with the detection of rarer mutation types, as well as other influencing factors, including CF birthrate, family planning and prenatal testing and fertility procedures, relating to assisted reproductive technology (<italic toggle="yes">in vitro</italic> fertilisation and intrauterine insemination) and pre-implantation genetic screening.<xref rid="b18" ref-type="bibr">18</xref></p><p>Changes in F508del prevalence are noted in various age groups, illustrated in <xref rid="f03" ref-type="fig">Figure 3A</xref> and <xref rid="f04" ref-type="fig">Figure 3B</xref>. In older Northern Ireland CF age groups, F508del heterozygous individuals&#8217; prevalence is higher and F508del homozygous lower i.e., 35.7% in the 20-23-age group and 82.6% in &gt;55-year-olds (heterozygous F508del), and 50.0% in the 20-23-age group to 4.3% in &gt;55-year-olds (homozygous F508del). F508del homozygous individuals often have severe disease phenotypes, dying younger and those with severe mutations have a ten-year-lower estimated median survival age than those with mild mutations,<xref rid="b5" ref-type="bibr">5</xref> possibly explaining lower incidences in older age groups. F508del heterozygous individuals may live longer due to less severe disease, especially when combined with a mild second mutation, resulting in the dominant phenotype.<xref rid="b5" ref-type="bibr">5</xref> Scotet and colleagues reported a similar finding to this current study in relation to a lower proportion of F508del homozygous individuals with increasing age<xref rid="b5" ref-type="bibr">5</xref>. Likewise, a similar trend was noted in Dutch CF Registry reports, where a lower homozygous frequency in over 48-year-olds was recorded than in 12-17-year-olds i.e., 20.0% and 65.0% respectively.<xref rid="b19" ref-type="bibr">19</xref></p></sec><sec><title>Comparison of Northern Ireland CFTR allele frequencies with other countries</title><p>There is wide CF mutational heterogeneity worldwide, with mutation spectrum and frequency highly influenced by ethnic background and geographical location.<xref rid="b20" ref-type="bibr">20</xref> CFTR mutation rates are highest in European Caucasian populations at 1 in 2,500 live births.<xref rid="b21" ref-type="bibr">21</xref> Incidence is less common in native Africans (1 in 17,000), and in Asian UK migrants (1 in 10,000 -12,000),<xref rid="b7" ref-type="bibr">7</xref> with prevalence increasing from the Mediterranean basin to Northern Europe.<xref rid="b5" ref-type="bibr">5</xref> Few mutations reach worldwide frequencies above 0.1%<xref rid="b20" ref-type="bibr">20</xref> and frequencies vary due to genetic drift, changes in allele frequency over generations due to random parental population allele proportion fluctuations,<xref rid="b17" ref-type="bibr">17</xref> isolation, and the founder effect - an extreme version of genetic drift occurring when individuals become isolated from a larger population.<xref rid="b5" ref-type="bibr">5</xref> The four most common Northern Ireland CFTR variants compared worldwide and with countries within the British Isles are shown in <xref rid="t03" ref-type="table">Table 3</xref> and <xref rid="f02" ref-type="fig">Figure 2</xref>.</p><p>Northern Ireland&#8217;s CFTR distribution of the F508del mutation is unlike any of its closest geographical neighbours, including Ireland, England, Scotland and Wales (<xref rid="t03" ref-type="table">Table 3</xref> &amp; <xref rid="t04" ref-type="table">Table 4</xref>). Northern Ireland has a lower proportion of F508del homozygous (34.2%) and a higher prevalence of F508del heterozygous (51.5%), than its neighbours. The F508del mutation is ubiquitous and the most common CFTR variant worldwide.<xref rid="b22" ref-type="bibr">22</xref> This is believed to have arisen in Europe over 52,000 years ago, spreading West to East, in chronologically distinct expansions, resulting in differential F508del frequencies in Europe and beyond.<xref rid="b22" ref-type="bibr">22</xref> It is hypothesised that F508del heterozygous individuals had a selective advantage due to high prevalence among native Europeans, possibly an increased resistance to intestinal diseases, known as heterozygous resistance,<xref rid="b23" ref-type="bibr">23</xref> explaining its high allelic frequency, however this benefit remains elusive.<xref rid="b24" ref-type="bibr">24</xref> From <xref rid="t03" ref-type="table">Table 3</xref>, it is evident that the frequency of mutations not in the Northern Ireland top four, increases further from Caucasian populations of America, UK, Europe, and Australia, reflected by high percentages of other mutations in India, Iran, and Brazil. The F508del mutation exhibits substantial regional variation from 27% of alleles in Turkey, 26% in Algeria, to 87% in Denmark.<xref rid="b25" ref-type="bibr">25</xref> In Northern Ireland, F508del frequency was 62.3%, and lower than the worldwide average of 73.1%, but similar to Europe&#8217;s average of 60.3%. USA and Australian F508del frequencies are higher at 85.8% and 89.1%, respectively, suggesting prevalence may increase westward.</p><p>R117H was the second most common Northern Ireland CF allele at 8.9%, higher than the worldwide average of 2% and the European average of 1%, with highest frequencies reported in neighbouring Ireland at 3.2%<xref rid="b26" ref-type="bibr">26</xref> and Australia at 1.8%<xref rid="b27" ref-type="bibr">27</xref>. G551D was the third most common Northern Ireland allele, and 5.0%, higher than the worldwide average of 3.3%. This mutation is most frequent non-F508del mutation in Ireland (8.3%)<xref rid="b26" ref-type="bibr">26</xref> and within many celtic cultures.</p><p>Such differences in the frequency of F508del mutations, particularly the ratio of homozygous to heterozygous populations, in the contemporary Northern Ireland population merits further reflection. A number of related interesting questions await an answer. Historically, one hypothesis relating to differences in CFTR gene frequencies is that CF gene mutations, particularly F508del was enriched due to the protective effect against secretory diarrhoeas which CF conferred on those with the condition, when exposed to pathogenic bacteria from domesticated cattle, which were transmitted zoonotically. This was particularly the case in populations in Northern Europe, which spread southwards in tandem with cattle pastoralism.<xref rid="b28" ref-type="bibr">28</xref> There is controversy regarding whether or not, wild oxen ever inhabited ancient Ireland. Scharff&#8217;s treatise on the &#8220;<italic toggle="yes">Origins of Irish Cattle</italic>&#8221; suggests that this was the case and that cattle (<italic toggle="yes">Bos longifrons</italic>) were introduced to Ireland long ago, certainly pre-Christian times by early settlers.<xref rid="b29" ref-type="bibr">29</xref> Rutimeyer described three distinct lineages of cattle, namely <italic toggle="yes">trochoceros, primigenius</italic> and <italic toggle="yes">brachyceros</italic>, from archaeological remains, which had lived in Switzerland during the Stone Age.<xref rid="b30" ref-type="bibr">30</xref> It is interesting to note that <italic toggle="yes">brachyceros</italic> are ancestors of the modern Kerry breed of cattle today. Rutimeyer also noted that the same breed has been found in ancient archaeological deposits in Great Britain, Sweden, Holland and other parts of Europe.<xref rid="b30" ref-type="bibr">30</xref> This evidence of the early origins of cattle in Ireland may offer supporting evidence of a migration of domesticated cattle and a CFTR (F508del)-enriched population of herders coming to Ireland, as part of the expansion of cattle pastoralism across European. Certainly, by the 7<sup>th</sup> and 8<sup>th</sup> centuries, the presence of cattle in Ulster is documented in Gaelic literature, as documented in <italic toggle="yes">An T&#225;in B&#243; C?ailgne</italic> (<italic toggle="yes">The Cattle Raid of Cooley</italic>), narrating the story of the theft of Donn Cuailnge (the brown bull of Cooley) from his owner, D&#225;ire MacFiachna, by Queen Medb of Connacht. However, the geographical isolation of Ireland as an island, sitting west of its neighbouring island, Great Britain, which sits west of continental Europe, may suggest that ethnic diaspora of people and their domesticated livestock may have been limited due to the island effect, physically limiting their free movement.</p><p>Historically in Ulster (<italic toggle="yes">circa</italic> to the 19<sup>th</sup> century), the island effect, the effect of limited movement of people, limited travel opportunities, poor modes of transportation, a relatively poor infrastructure and a lack of social mobility, combined with political, religious, social and cultural factors, may have limited the diversity and richness of the provincial gene pool. The importance of consanguinity data in human genetic studies has been previously stressed.<xref rid="b31" ref-type="bibr">31</xref> There are two historic reports dealing with consanguinity in Ireland, where in 1883, Cameron reported that in 7,567 persons investigated, 43 (0.57%) were or said they were children of first cousins.<xref rid="b32" ref-type="bibr">32</xref> A latter study in 1955 by Kilpatrick and colleagues reported that it was unlikely that the full-cousin marriage rate in Northern Ireland was as much as 1%.<xref rid="b33" ref-type="bibr">33</xref> A further study published in 1970 by Masterson indicated a first-cousin marriage rate in Catholic marriages during the period 1959-1968, of 0.032% for the dioceses of Derry, 0.069% (Down and Connor), 0.066% (Armagh), 0.075% (Clogher) and 0.000% (Dromore).<xref rid="b31" ref-type="bibr">31</xref> Masterson concluded that the incidence of first cousin marriages during the study period was lower and possibly lower than those reported by Freire-Maia, for most European countries.<xref rid="b31" ref-type="bibr">31</xref> These data therefore suggest inverse proportionality and a counter-support for consanguinity in relation to the relatively high incidence of CF in Ireland.</p><p>The effects on the CFTR mutational gene pool on mass historical migrations into Ulster requires analysis. Two mass migrations into Ulster dominate this social anthropological landscape.<xref rid="b34" ref-type="bibr">34</xref> These would have had a significant redistribution of the <italic toggle="yes">status quo</italic> of CFTR genotypes, but to what extent remains unknown. Firstly, the migration of the Hugenots from France to Ireland following the Revocation of the Edict of Nantes by Louis XIV in 1685, saw approximately 5,000 Hugenots settle in Ireland.<xref rid="b35" ref-type="bibr">35</xref> In Ulster, they settled mainly in Lisburn, as well as in Castleblaney, Co. Monaghan and Killeshandra, Co. Cavan.<xref rid="b35" ref-type="bibr">35</xref></p><p>Secondly, the mass migration of Scottish and English settlers to Ulster, as part of the Plantation of Ulster, is of particular significance.<xref rid="b34" ref-type="bibr">34</xref> The majority of the Ulster plantation occurred from 1609 and by the mid 1600s, after the Cromwellian conquest of 1652, Gaelic clan chiefs had been crushed and their lands seized for plantation with predominantly Scottish Lowland planters, as well as with English settlers. Scottish immigrants to Ulster continued and increased in frequency due to famine in Scotland, during the Seven Lean Years in the 1690s.<xref rid="b34" ref-type="bibr">34</xref> It is estimated that the population of Ulster in 1630 was 240,000 comprising of 200,00 Irish and 40,000 British with the Irish figure taken from the Muster Rolls for circa 1630.<xref rid="b36" ref-type="bibr">36</xref> From 1650 to 1700, 100,000 settlers have been estimated to have migrated from Britain to Ulster, of which half of them were English.<xref rid="b34" ref-type="bibr">34</xref> Additionally, in the 20 years following William III&#8217;s victory in 1690, it is estimated that approximately 50,000 Scots arrived in Ulster. This represents a significant dilution of the existing gene pool with predominantly Scottish, as well as English CFTR mutational genes. The frequency of F508del homozygous, as well as heterozygous genotypes from Northern Ireland, align most closely with Scottish values, compared to Irish and English frequencies, as shown in <xref rid="t03" ref-type="table">Table 3</xref>.</p><p>It is interesting to note the dynamics of CFTR genotype stability within the Northern Ireland CF population (<xref rid="t04" ref-type="table">Table 4</xref>). Over approximately two and a half decades (1996-2021), 23 CFTR mutations remain shared. The six most frequently detected CFTR mutations accounted for 84.4% of all alleles. Six alleles, which were described in the 1996 CFTR analysis, were absent from the 2021 data, whilst there were additional descriptions of 39 allelic mutations, which occurred in the 2021 analysis, but which were not described in the 1996 analysis. It is interesting to note the absence of these six mutation types described in the 1996 analysis, but absent in the 2021 analysis. It is unknown if these mutational types will reappear as CFTR types in the future, as this will be largely dependent on the frequency of prevalence of such mutation types in the population at any given time. Therefore, CFTR mutation types which are extremely rare in the population will experience large states of flux in their reporting. Furthermore, it is likely that the presence of additional CFTR mutation types in 2021 potentially reflect technological advances in DNA molecular analyses, particularly sequencing, and the formal establishment of agreed international mutation types, thereby enabling the reporting of rarer types locally.</p><p>In conclusion, characterisation of CFTR mutation alleles from people with cystic fibrosis provides essential information to help predict disease severity and effect of targeted CFTR modulator therapy. The arrival of CFTR modulator therapy has the potential to radically alter the current <italic toggle="yes">status quo</italic> due to significant improvements in lung function and quality of life, resulting in increased independent living and fertility.</p></sec></sec></body><back><ack><title>Acknowledgements</title><p>The authors wish to acknowledge with thanks, Dr Karen Raraigh, Curator of the Clinical and Functional TRanslation of CFTR (CFTR2) dataset, Johns Hopkins University, Baltimore USA, for guidance in the classification terminologies used in relation to CFTR mutations.</p></ack><fn-group><title>Transparency declarations/Conflict of Interest</title><fn fn-type="COI-statement"><p>The authors declare that the research was conducted in the absence of any commercial, financial or other relationships that could be construed as a potential conflict of interest.</p></fn></fn-group><fn-group><title>Funding</title><fn fn-type="financial-disclosure"><p>This study was supported by internal funding.</p></fn></fn-group><fn-group><fn fn-type="other"><p>UMJ is an open access publication of the Ulster Medical Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.ums.ac.uk" ext-link-type="uri">http://www.ums.ac.uk</ext-link>).</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="b1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Veit</surname><given-names>G</given-names></name><name name-style="western"><surname>Avramescu</surname><given-names>RG</given-names></name><name name-style="western"><surname>Chiang</surname><given-names>AN</given-names></name><name name-style="western"><surname>Houck</surname><given-names>SA</given-names></name><name name-style="western"><surname>Cai</surname><given-names>Z</given-names></name><name name-style="western"><surname>Peters</surname><given-names>KW</given-names></name><etal/></person-group><article-title>From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations</article-title><source>Mol Biol Cell</source><year>2016</year><volume>27</volume><issue>3</issue><fpage>424</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">26823392</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1091/mbc.E14-04-0935</pub-id><pub-id pub-id-type="pmcid">PMC4751594</pub-id></element-citation></ref><ref id="b2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harutyunyan</surname><given-names>M</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Mun</surname><given-names>KS</given-names></name><name name-style="western"><surname>Yang</surname><given-names>F</given-names></name><name name-style="western"><surname>Arora</surname><given-names>K</given-names></name><name name-style="western"><surname>Naren</surname><given-names>AP</given-names></name></person-group><article-title>Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations</article-title><source>Amer J Physiol</source><year>2018</year><volume>314</volume><issue>4</issue><fpage>529</fpage><lpage>43</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/ajplung.00465.2017</pub-id><pub-id pub-id-type="pmcid">PMC5966781</pub-id><pub-id pub-id-type="pmid">29351449</pub-id></element-citation></ref><ref id="b3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shteinberg</surname><given-names>M</given-names></name><name name-style="western"><surname>Haq</surname><given-names>IJ</given-names></name><name name-style="western"><surname>Polineni</surname><given-names>D</given-names></name><name name-style="western"><surname>Davies</surname><given-names>JC</given-names></name></person-group><article-title>Cystic fibrosis</article-title><source>Lancet</source><year>2021</year><volume>397</volume><issue>10290</issue><fpage>2195</fpage><lpage>211</lpage><pub-id pub-id-type="pmid">34090606</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)32542-3</pub-id></element-citation></ref><ref id="b4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deletang</surname><given-names>K</given-names></name><name name-style="western"><surname>Taulan-Cadars</surname><given-names>M</given-names></name></person-group><article-title>Splicing mutations in the CFTR gene as therapeutic targets</article-title><source>Gene Ther</source><year>2022</year><volume>29</volume><issue>7-8</issue><fpage>399</fpage><lpage>406</lpage><pub-id pub-id-type="pmid">35650428</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41434-022-00347-0</pub-id><pub-id pub-id-type="pmcid">PMC9385490</pub-id></element-citation></ref><ref id="b5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scotet</surname><given-names>V</given-names></name><name name-style="western"><surname>L&#8217;Hostis</surname><given-names>C</given-names></name><name name-style="western"><surname>F&#233;rec</surname><given-names>C</given-names></name></person-group><article-title>The changing epidemiology of cystic fibrosis: Incidence, survival and impact of the CFTR Gene Discovery</article-title><source>Genes (Basel)</source><year>2020</year><volume>11</volume><issue>6</issue><fpage>589</fpage><pub-id pub-id-type="doi">10.3390/genes11060589</pub-id><pub-id pub-id-type="pmid">32466381</pub-id><pub-id pub-id-type="pmcid">PMC7348877</pub-id></element-citation></ref><ref id="b6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pereira</surname><given-names>SV</given-names></name><name name-style="western"><surname>Ribeiro</surname><given-names>JD</given-names></name><name name-style="western"><surname>Ribeiro</surname><given-names>AF</given-names></name><name name-style="western"><surname>Bertuzzo</surname><given-names>CS</given-names></name><name name-style="western"><surname>Marson</surname><given-names>FA</given-names></name></person-group><article-title>Novel, rare and common pathogenic variants in the CFTR gene screened byhigh-throughput sequencing technology and predicted by in silico tools</article-title><source>Sci Rep</source><year>2019</year><volume>9</volume><issue>1</issue><fpage>6234</fpage><pub-id pub-id-type="doi">10.1038/s41598-019-42404-6</pub-id><pub-id pub-id-type="pmid">30996306</pub-id><pub-id pub-id-type="pmcid">PMC6470152</pub-id></element-citation></ref><ref id="b7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prasad</surname><given-names>R</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>H</given-names></name><name name-style="western"><surname>Kaur</surname><given-names>G</given-names></name></person-group><article-title>Molecular basis of cystic fibrosis disease: an Indian perspective</article-title><source>Indian J Clin Biochem</source><year>2010</year><volume>25</volume><issue>4</issue><fpage>335</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">21966101</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12291-010-0091-1</pub-id><pub-id pub-id-type="pmcid">PMC2994562</pub-id></element-citation></ref><ref id="b8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>AC</given-names></name><name name-style="western"><surname>Turvey</surname><given-names>SE</given-names></name><name name-style="western"><surname>Alves</surname><given-names>MP</given-names></name><name name-style="western"><surname>Regamey</surname><given-names>N</given-names></name><name name-style="western"><surname>T&#252;mmler</surname><given-names>B</given-names></name><name name-style="western"><surname>Hartl</surname><given-names>D</given-names></name></person-group><article-title>Current concepts: host-pathogen interactions in cystic fibrosis airways disease</article-title><source>Eur Respir Rev</source><year>2014</year><volume>23</volume><issue>133</issue><fpage>320</fpage><lpage>2</lpage><pub-id pub-id-type="pmid">25176968</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1183/09059180.00006113</pub-id><pub-id pub-id-type="pmcid">PMC9487317</pub-id></element-citation></ref><ref id="b9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lipuma</surname><given-names>JJ</given-names></name></person-group><article-title>The changing microbial epidemiology in cystic fibrosis</article-title><source>Clin Microbiol Rev</source><year>2010</year><volume>23</volume><issue>2</issue><fpage>299</fpage><lpage>323</lpage><pub-id pub-id-type="pmid">20375354</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/CMR.00068-09</pub-id><pub-id pub-id-type="pmcid">PMC2863368</pub-id></element-citation></ref><ref id="b10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blanchard</surname><given-names>AC</given-names></name><name name-style="western"><surname>Waters</surname><given-names>VJ</given-names></name></person-group><article-title>Microbiology of cystic fibrosis airway disease</article-title><source>Semin Respir Crit Care Med</source><year>2019</year><volume>40</volume><issue>6</issue><fpage>727</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">31887768</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1055/s-0039-1698464</pub-id><pub-id pub-id-type="pmcid">PMC7117079</pub-id></element-citation></ref><ref id="b11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hughes</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Hill</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Macek</surname><given-names>M</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Redmond</surname><given-names>AO</given-names></name><name name-style="western"><surname>Nevin</surname><given-names>NC</given-names></name><name name-style="western"><surname>Graham</surname><given-names>CA</given-names></name></person-group><article-title>Mutation characterization of CFTR gene in 206 Northern Irish CF families:thirty mutations, including two novel, accountforapproximately94% of CF chromosomes</article-title><source>Hum Mutat</source><year>1996</year><volume>8</volume><issue>4</issue><fpage>340</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">8956039</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/(SICI)1098-1004(1996)8:4&lt;340::AID-HUMU7&gt;3.0.CO;2-B</pub-id></element-citation></ref><ref id="b12"><label>12.</label><element-citation publication-type="webpage"><collab>CFTR2</collab><source>The Clinical and Functional TRanslation of CFTR (CFTR2). [Internet]</source><comment>cited 2025 May 30. Available from <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://cftr2.org" ext-link-type="uri">http://cftr2.org</ext-link></comment></element-citation></ref><ref id="b13"><label>13.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Russell</surname><given-names>R</given-names></name></person-group><source>Research and Information Service Research Paper. Migrationin Northern Ireland: an update. NIAR 10-12. Paper 31/12. [Internet]</source><publisher-loc>Belfast</publisher-loc><publisher-name>Northern Ireland Assembly: Research and Information Service</publisher-name><year>2012</year><comment>cited 2025 May 30. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.niassembly.gov.uk/globalassets/documents/raise/publications/2012/general/3112.pdf" ext-link-type="uri">https://www.niassembly.gov.uk/globalassets/documents/raise/publications/2012/general/3112.pdf</ext-link></comment></element-citation></ref><ref id="b14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giannattasio</surname><given-names>S</given-names></name><name name-style="western"><surname>Bobba</surname><given-names>A</given-names></name><name name-style="western"><surname>Jurgelevicius</surname><given-names>V</given-names></name><name name-style="western"><surname>Vacca</surname><given-names>RA</given-names></name><name name-style="western"><surname>Lattanzio</surname><given-names>P</given-names></name><name name-style="western"><surname>Merafina</surname><given-names>RS</given-names></name><etal/></person-group><article-title>Molecular basis of cystic fibrosis in Lithuania: incomplete CFTR mutation detection by PCR-based screening protocols</article-title><source>Genet Test</source><year>2006</year><volume>10</volume><issue>3</issue><fpage>169</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">17020467</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/gte.2006.10.169</pub-id></element-citation></ref><ref id="b15"><label>15.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Zolin</surname><given-names>A</given-names></name><name name-style="western"><surname>Orenti</surname><given-names>A</given-names></name><name name-style="western"><surname>Naehrlich</surname><given-names>L</given-names></name><name name-style="western"><surname>Jung</surname><given-names>A</given-names></name><name name-style="western"><surname>van Rens</surname><given-names>J</given-names></name><etal/></person-group><source>ECFS Patient Registry: Annual Report 2018. [Internet]</source><publisher-loc>Denmark</publisher-loc><publisher-name>European Cystic Fibrosis Society</publisher-name><year>2019</year><comment>cited 2025 May 30. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ecfs.eu/sites/default/files/general-content-files/working-groups/ecfs-patient-registry/ECFSPR_Report_2018_v1.4.pdf" ext-link-type="uri">https://www.ecfs.eu/sites/default/files/general-content-files/working-groups/ecfs-patient-registry/ECFSPR_Report_2018_v1.4.pdf</ext-link></comment></element-citation></ref><ref id="b16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Masekela</surname><given-names>R</given-names></name><name name-style="western"><surname>Zampoli</surname><given-names>M</given-names></name><name name-style="western"><surname>Westwood</surname><given-names>AT</given-names></name><name name-style="western"><surname>White</surname><given-names>DA</given-names></name><name name-style="western"><surname>Green</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Olorunju</surname><given-names>S</given-names></name><etal/></person-group><article-title>Phenotypic expression of the 3120+1G&gt;A mutation in non-Caucasian children with cystic fibrosis in South Africa</article-title><source>J Cystic Fibros</source><year>2013</year><volume>12</volume><issue>4</issue><fpage>363</fpage><lpage>66</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jcf.2012.11.003</pub-id><pub-id pub-id-type="pmid">23206872</pub-id></element-citation></ref><ref id="b17"><label>17.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Shaikh</surname><given-names>N</given-names></name><name name-style="western"><surname>Lee</surname><given-names>A</given-names></name><name name-style="western"><surname>Charman</surname><given-names>S</given-names></name><name name-style="western"><surname>Cosgriff</surname><given-names>R</given-names></name><name name-style="western"><surname>Carr</surname><given-names>S</given-names></name></person-group><source>UK Cystic Fibrosis Registry 2020 Annual Data Report. [Internet]. Cystic fibrosis strength in numbers</source><publisher-loc>London</publisher-loc><publisher-name>Cystic Fibrosis Trust</publisher-name><year>2020</year><comment>cited 2025 May 30. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cysticfibrosis.org.uk/sites/default/files/2021-12/CF_Annual%20Report%202020_V8.pdf" ext-link-type="uri">https://www.cysticfibrosis.org.uk/sites/default/files/2021-12/CF_Annual%20Report%202020_V8.pdf</ext-link></comment></element-citation></ref><ref id="b18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jain</surname><given-names>R</given-names></name><name name-style="western"><surname>Kazmerski</surname><given-names>TM</given-names></name><name name-style="western"><surname>Zuckerwise</surname><given-names>LC</given-names></name><name name-style="western"><surname>West</surname><given-names>NE</given-names></name><name name-style="western"><surname>Montemayor</surname><given-names>K</given-names></name><name name-style="western"><surname>Aitken</surname><given-names>ML</given-names></name><etal/></person-group><article-title>Pregnancy in cystic fibrosis: Review of the literature and expert recommendations</article-title><source>J Cyst Fibros</source><year>2022</year><volume>21</volume><issue>3</issue><fpage>387</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">34456158</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jcf.2021.07.019</pub-id></element-citation></ref><ref id="b19"><label>19.</label><element-citation publication-type="book"><collab>Nederlandse Cystic Fibrosis Stichting</collab><source>Dutch Cystic Fibrosis Registry: dataon people with cystic fibrosis in the Netherlands. [Internet]. Annual report for 2020. F Foundation (NCFS). Dutch CF Registry 2020</source><publisher-loc>Baarn</publisher-loc><publisher-name>Nederlandse Cystic Fibrosis Stichting</publisher-name><year>2021</year><comment>cited 2025 May 30. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://ncfs.nl/wp-content/uploads/2024/03/211011_NCFR-report2020-English-complete.pdf" ext-link-type="uri">https://ncfs.nl/wp-content/uploads/2024/03/211011_NCFR-report2020-English-complete.pdf</ext-link></comment></element-citation></ref><ref id="b20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>B</given-names></name><name name-style="western"><surname>Cao</surname><given-names>L</given-names></name></person-group><article-title>Differences in gene mutations between Chinese and Caucasian cyctisc fibrosis patients</article-title><source>Pediatr Pulmonol</source><year>2017</year><volume>52</volume><issue>3</issue><fpage>E11</fpage><lpage>E14</lpage><pub-id pub-id-type="doi">10.1002/ppul.23539</pub-id><pub-id pub-id-type="pmid">27717243</pub-id><pub-id pub-id-type="pmcid">PMC5324682</pub-id></element-citation></ref><ref id="b21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lao</surname><given-names>O</given-names></name><name name-style="western"><surname>Andr&#233;s</surname><given-names>AM</given-names></name><name name-style="western"><surname>Mateu</surname><given-names>E</given-names></name><name name-style="western"><surname>Bertranpetit</surname><given-names>J</given-names></name><name name-style="western"><surname>Calafell</surname><given-names>F</given-names></name></person-group><article-title>Spatial patterns of cystic fibrosis mutation spectra in European populations</article-title><source>Eur J Hum Genet</source><year>2003</year><volume>11</volume><issue>5</issue><fpage>385</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1038/sj.ejhg.5200970</pub-id><pub-id pub-id-type="pmid">12734544</pub-id></element-citation></ref><ref id="b22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morral</surname><given-names>N</given-names></name><name name-style="western"><surname>Bertranpetit</surname><given-names>J</given-names></name><name name-style="western"><surname>Estivill</surname><given-names>X</given-names></name><name name-style="western"><surname>Nunes</surname><given-names>V</given-names></name><name name-style="western"><surname>Casals</surname><given-names>T</given-names></name><name name-style="western"><surname>Gim&#233;nez</surname><given-names>J</given-names></name><etal/></person-group><article-title>The origin of the major cystic fibrosis mutation (delta F508) in European populations</article-title><source>Nat Genet</source><year>1994</year><volume>7</volume><issue>2</issue><fpage>169</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1038/ng0694-169</pub-id><pub-id pub-id-type="pmid">7920636</pub-id></element-citation></ref><ref id="b23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farrell</surname><given-names>PM</given-names></name><name name-style="western"><surname>Rock</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Baker</surname><given-names>MW</given-names></name></person-group><article-title>The Impact of the CFTR gene discoveryon cystic fibrosis diagnosis, counseling, and preventive therapy</article-title><source>Genes (Basel)</source><year>2020</year><volume>11</volume><issue>4</issue><fpage>401</fpage><pub-id pub-id-type="doi">10.3390/genes11040401</pub-id><pub-id pub-id-type="pmid">32276344</pub-id><pub-id pub-id-type="pmcid">PMC7231248</pub-id></element-citation></ref><ref id="b24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lyczak</surname><given-names>JB</given-names></name><name name-style="western"><surname>Cannon</surname><given-names>CL</given-names></name><name name-style="western"><surname>Pier</surname><given-names>GB</given-names></name></person-group><article-title>Lung infections associated with cystic fibrosis</article-title><source>Clin Microbiol Rev</source><year>2002</year><volume>15</volume><issue>2</issue><fpage>94</fpage><lpage>222</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/CMR.15.2.194-222.2002</pub-id><pub-id pub-id-type="pmcid">PMC118069</pub-id><pub-id pub-id-type="pmid">11932230</pub-id></element-citation></ref><ref id="b25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Bowman</surname><given-names>MC</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>E</given-names></name><name name-style="western"><surname>Wertz</surname><given-names>K</given-names></name><name name-style="western"><surname>Wong</surname><given-names>LJ</given-names></name></person-group><article-title>A novel mutation in the CFTR gene correlates with severe clinical phenotype in seven Hispanic patients</article-title><source>J Med Genet</source><year>2000</year><volume>37</volume><issue>3</issue><fpage>215</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">10777364</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jmg.37.3.215</pub-id><pub-id pub-id-type="pmcid">PMC1734535</pub-id></element-citation></ref><ref id="b26"><label>26.</label><element-citation publication-type="book"><collab>Cystic Fibrosis Registry of Ireland (CFRI)</collab><source>2019 Annual Report CF Registry of Ireland. [Internet]</source><publisher-loc>Dublin</publisher-loc><publisher-name>CFRI</publisher-name><year>2020</year><comment>[cited 2025 May 30]. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://cfri.ie/annual-reports/" ext-link-type="uri">https://cfri.ie/annual-reports/</ext-link></comment></element-citation></ref><ref id="b27"><label>27.</label><element-citation publication-type="book"><collab>Cystic Fibrosis Australia</collab><source>Australian Cystic Fibrosis Data Registry: AnnualReport 2020 [Internet]</source><publisher-loc>Melbourne</publisher-loc><publisher-name>Monash University. Australian Cystic Fibrosis Data Registry</publisher-name><comment>cited 2025 May 30. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cfsa.org.au/wp-content/uploads/2022/03/ACFDR-2020-Annual-Report-V1-1.pdf" ext-link-type="uri">https://www.cfsa.org.au/wp-content/uploads/2022/03/ACFDR-2020-Annual-Report-V1-1.pdf</ext-link></comment></element-citation></ref><ref id="b28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alfonso-S&#225;nchez</surname><given-names>MA</given-names></name><name name-style="western"><surname>P&#233;rez-Miranda</surname><given-names>AM</given-names></name><name name-style="western"><surname>Garc&#237;a-Obreg&#243;n</surname><given-names>S</given-names></name><name name-style="western"><surname>Pe&#241;a</surname><given-names>JA</given-names></name></person-group><article-title>An evolutionary approach to the high frequency of the Delta F508 CFTR mutation in European populations</article-title><source>Med Hypotheses</source><year>2010</year><volume>74</volume><issue>6</issue><fpage>989</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">20110149</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mehy.2009.12.018</pub-id></element-citation></ref><ref id="b29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scharff</surname><given-names>RF</given-names></name></person-group><article-title>On the origin of the Irish cattle</article-title><source>Irish Naturalist</source><year>1923</year><volume>32</volume><issue>7</issue><fpage>65</fpage><lpage>76</lpage></element-citation></ref><ref id="b30"><label>30.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Rutimeyer</surname><given-names>L</given-names></name></person-group><source>Die Fauna der Pfahlbauten der Schweiz</source><publisher-loc>Basel</publisher-loc><publisher-name>Switzerland</publisher-name><year>1861</year><fpage>1</fpage><lpage>248</lpage></element-citation></ref><ref id="b31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Masterson</surname><given-names>JG</given-names></name></person-group><article-title>Consanguinity in Ireland</article-title><source>Hum Heredity</source><year>1970</year><volume>20</volume><issue>4</issue><fpage>37182</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000152333</pub-id><pub-id pub-id-type="pmid">5512370</pub-id></element-citation></ref><ref id="b32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cameron</surname><given-names>CH</given-names></name></person-group><article-title>Consanguineous marriages in relation to deaf-mutism</article-title><source>Trans Acad Med Ireland</source><year>1883</year><volume>1</volume><fpage>214</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1007/BF03171592</pub-id></element-citation></ref><ref id="b33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kilpatrick</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Mathers</surname><given-names>JD</given-names></name><name name-style="western"><surname>Stevenson</surname><given-names>AC</given-names></name></person-group><article-title>The importance of populationfertility and consanguinity data being available in medico-social studies;some data on consanguineous marriages in Northern Ireland</article-title><source>Ulster Med J</source><year>1955</year><volume>24</volume><issue>2</issue><fpage>113</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">13299424</pub-id><pub-id pub-id-type="pmcid">PMC2480254</pub-id></element-citation></ref><ref id="b34"><label>34.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>MacRaild</surname><given-names>DM</given-names></name><name name-style="western"><surname>Smith</surname><given-names>M</given-names></name></person-group><article-title>Migration and Emigration, 1600&#8211;1945</article-title><person-group person-group-type="editor"><name name-style="western"><surname>Kennedy</surname><given-names>L</given-names></name><name name-style="western"><surname>Ollerenshaw</surname><given-names>P</given-names></name></person-group><source>Ulster since 1600: politics, economy, and society</source><publisher-loc>Oxford</publisher-loc><publisher-name>Oxford University Press</publisher-name><year>2012</year><pub-id pub-id-type="doi">10.1093/acprof:oso/9780199583119.001.0001</pub-id></element-citation></ref><ref id="b35"><label>35.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Hylton</surname><given-names>R</given-names></name></person-group><source>Ireland&#8217;s Huguenots and their refuge, 1662-1745. An unlikely haven</source><year>2013</year><publisher-loc>Liverpool</publisher-loc><publisher-name>Liverpool University Press</publisher-name></element-citation></ref><ref id="b36"><label>36.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name name-style="western"><surname>Macafee</surname><given-names>W</given-names></name></person-group><source>Ulster Historical Foundation. The Ulster Plantation. Movement of British Settlers into Ulster in the 17th Century</source><comment>cited 2025 July 22. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://ulsterhistoricalfoundation.com/ulster-plantation/movement-of-british-settlers" ext-link-type="uri">https://ulsterhistoricalfoundation.com/ulster-plantation/movement-of-british-settlers</ext-link></comment></element-citation></ref></ref-list></back></article></pmc-articleset>